Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 31

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 31
---
, or at, the Meeting in accordance with the procedures described in the proxy statement, will be voted as specified in the instructions indicated in such proxies. Subject to applicable law, in the absence of instructions, the shares represented by properly executed and received proxies will be voted “FOR” all of the proposed resolutions to be presented at the Meeting for which the Board recommends a vote “FOR” Proposals 1 through 14. For all disputes arising out of or in connection with this Proxy, the ordinary courts at the registered domicile of the Company are exclusively competent. All obligations and rights arising out of or in connection with this proxy are governed by Swiss Law The undersigned herewith expressively declares to indemnify the proxy or the substitutes for any direct or indirect damages arising out of or in connection with the actions referred to in this proxy card. This proxy also delegates, to the extent permitted by applicable law, discretionary authority to vole with respect to all other business and legal acts which the undersigned could carry out in the event of his/her/its personal presence at the annual meeting of shareholders as well as to make any changes required due lo objections by the commercial register and to any adjournment(s) or postponement(s) thereof. PLEASE COMPLETE. DATE AND SIGN THIS FORM OF PROXY AND E-MAIL OR MAIL THE ENTIRE PROXY PROMPTLY, IN ACCORDANCE WITH THE INFORMATION PROVIDED ON THE FRONT PAGE, IN ORDER TO ASSURE REPRESENTATION OF YOUR SHARES. IF THE FORM OF PROXY IS MAILED IN THE UNITED STATES IN THE ENCLOSED ENVELOPE, NO POSTAGE NEED BE AFFIXED. Date Signature Signature, if held jointly ___________________ _________________________________ _________________________________ To change the address on your account, please check the box at right and indicate your new address. * SPECIMEN * [ ] [ ] REFERENCES TO ADDITIONAL INFORMATION This proxy statement/prospectus incorporates important business and financial information about NLS that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (the “SEC”) website ( www.sec.gov) or upon your written or oral request by contacting the Chief Executive Officer of NLS Pharmaceutics Ltd., at The Circle6, 8058 Zurich, Switzerland, or by calling +41.44.512.2150. To facilitate timely delivery of these documents, any request should be made no later than, 2025 to receive them before theextraordinary meeting of shareholders of NLS (the “NLS